EQS-News: Secarna Pharmaceuticals announces publication of new preclinical data showing durable antitumor activity of LNAplus™-based ASOs that both stimulate the innate immune system and suppress PD-L1 expressi

TLR9 signaling is an important innate immune pathway that is relevant as a first-line defense mechanism against pathogens.